Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly.
about
Optimal dosage interval for depot somatostatin analogue therapy in acromegaly requires individual titration.Somatostatin analogs: a new tool for the management of Graves' ophthalmopathy.GH receptor antagonist: mechanism of action and clinical utility.Comparison of octreotide LAR and lanreotide autogel as post-operative medical treatment in acromegalyPhase III, double-blind study of depot octreotide versus placebo in the prevention of acute diarrhea in patients receiving pelvic radiation therapy: results of North Central Cancer Treatment Group N00CAMedical therapy of pituitary adenomas: effects on tumor shrinkage.Management of aggressive pituitary adenomas: current treatment strategies.Effects of lanreotide SR and Autogel on tumor mass in patients with acromegaly: a systematic review.Lanreotide for the treatment of acromegaly.Medical therapy in acromegaly.Effect of gender and gonadal status on the long-term response to somatostatin analogue treatment in acromegaly.GH/IGF-I normalization and tumor shrinkage during long-term treatment of acromegaly by lanreotide.Therapeutic options in the management of acromegaly: focus on lanreotide Autogel.Growth hormone responses to oral glucose and intravenous thyrotropin-releasing hormone in acromegalic patients treated by slow-release lanreotide.Prevalence of thyroid diseases in patients with acromegaly: results of an Italian multi-center study.Pharmacokinetics of a new Autogel formulation of the somatostatin analogue lanreotide after a single subcutaneous dose in healthy volunteers.One-year follow-up of patients with acromegaly treated with fixed or titrated doses of lanreotide Autogel.Desensitization treatment for hypersensitivity reaction to octreotide in an acromegalic patient.Endoscopic transphenoidal surgery for acromegaly improves quality of life.Ultrasonographic evidence of joint thickening reversibility in acromegalic patients treated with lanreotide for 12 months.Comparison of six months therapy with octreotide versus lanreotide in acromegalic patients: a retrospective study.
P2860
Q33422743-041D84E3-BB9B-4BB0-A559-A26923F4605CQ35785161-6F59AA77-A8C0-4DA5-A2E5-FB4D64556077Q36042428-3ED7F585-D498-402F-A747-0CDDE8440857Q36236809-60C90EF1-7C00-4AF1-B54B-6A951D3D2C4FQ37119415-DF8086A0-8BA9-40DC-B657-DFF75F55FFE5Q37268893-95E48B56-E583-4204-8F11-3FFE6E481D52Q37323609-241DD5D3-A072-4EEE-B5D7-E0533F076B8AQ37384392-38DC5412-74DF-414C-A9B1-1FDB59321B8EQ37521920-7CB357D8-883F-437A-816E-DF491BC86E70Q37859250-188E5799-C0CB-4B85-AD19-F66842FDC3C0Q42483024-7B82B2B6-3BA7-4E03-ABC8-4143E960A132Q42505176-F862D579-0567-47ED-8C09-4530CD5775BAQ43078115-0B70BD64-A7C9-48B6-9820-3B20BA07D152Q43640997-37AA9AA2-65C7-4A61-81A1-903663667312Q43949709-C5EF8B86-BFEC-42E4-B108-B67FCEAE67F2Q44852640-3FBCE938-4CBF-4B0A-8AE9-F79109469A1CQ44910768-F9D28D77-C2BA-4D1B-80CD-1C66B75D2145Q47726453-F34FEC93-8950-41D6-9A96-E170147BEF72Q48058744-2FF36D6E-0355-4860-8436-023CD882A360Q51559408-1E87BC5B-D3C4-4928-B74F-D81B74D7E128Q53925916-0396A717-F7C6-4C35-A078-E0651BC9ACF8
P2860
Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年学术文章
@wuu
1999年学术文章
@zh
1999年学术文章
@zh-cn
1999年学术文章
@zh-hans
1999年学术文章
@zh-my
1999年学术文章
@zh-sg
1999年學術文章
@yue
1999年學術文章
@zh-hant
name
Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly.
@en
Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly.
@nl
type
label
Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly.
@en
Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly.
@nl
prefLabel
Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly.
@en
Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly.
@nl
P2093
P2860
P356
P1476
Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly.
@en
P2093
A Di Sarno
C Di Somma
G Lombardi
P Marzullo
R Pivonello
P2860
P2888
P356
10.1007/BF03345477
P577
1999-01-01T00:00:00Z